ArticleFrontiers in oncology2025

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC.

Alessandro Tubita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.